Literature DB >> 23426567

Repeatability of the timed 25-foot walk test for individuals with multiple sclerosis.

Rebecca D Larson1, Daniel J Larson, Ted B Baumgartner, Lesley J White.   

Abstract

OBJECTIVE: The purpose of this study was to determine if there is a practice effect present in the timed 25-foot walk in ambulatory individuals with multiple sclerosis.
DESIGN: Thirty six people (30 women and 6 men) diagnosed with relapsing remitting multiple sclerosis participated in two testing sessions, one week apart. Each participant performed two sequential trials of the timed 25-foot walk test per session and the walk performance was measured with a laser timing system.
RESULTS: We observed improvements in walking speed between the two trials of session one (trial one: 6.42 (0.09) vs. trail two: 5.97 (0.08) seconds, p < 0.001). Within session two, performance remained stable (trial three: 5.71 (0.07) vs. trial four: 5.63 (0.07) seconds, p > 0.05). We also observed a significant improvement in walking speed when averages of the two trials were compared across sessions (session 1: 6.19 (0.09) vs. session 2: 5.67 (0.07) seconds, p < 0.01).
CONCLUSIONS: Based on our results, familiarization of the timed 25-foot walk test improves stability of walk performance scores in ambulatory individuals with relapsing remitting multiple sclerosis.

Entities:  

Keywords:  Multiple sclerosis; assessment; clinical tests; mobility; repeatability

Mesh:

Year:  2013        PMID: 23426567     DOI: 10.1177/0269215512470269

Source DB:  PubMed          Journal:  Clin Rehabil        ISSN: 0269-2155            Impact factor:   3.477


  7 in total

Review 1.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

2.  A Core Set of Outcome Measures for Adults With Neurologic Conditions Undergoing Rehabilitation: A CLINICAL PRACTICE GUIDELINE.

Authors:  Jennifer L Moore; Kirsten Potter; Kathleen Blankshain; Sandra L Kaplan; Linda C OʼDwyer; Jane E Sullivan
Journal:  J Neurol Phys Ther       Date:  2018-07       Impact factor: 3.649

3.  Skeletal muscle mitochondrial capacity in people with multiple sclerosis.

Authors:  Mary Ann Harp; Kevin K McCully; Marina Moldavskiy; Deborah Backus
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-11-15

4.  Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis.

Authors:  Sylvia Klineova; Rebecca Farber; Catarina Saiote; Colleen Farrell; Bradley N Delman; Lawrence N Tanenbaum; Joshua Friedman; Matilde Inglese; Fred D Lublin; Stephen Krieger
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-06-23

5.  Objective and subjective measures of dalfampridine efficacy in clinical practice.

Authors:  Sylvia Klineova; Rebecca Farber; Joshua Friedman; Colleen Farrell; Fred D Lublin; Stephen Krieger
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-07-09

6.  Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS).

Authors:  Georgios Tsivgoulis; Spyros Deftereos; Claudio Gobbi; Elisabeth Gulowsen Celius; Alina Kulakowska; Giorgia Maniscalco; Irene Mendes; Nicolaos Grigoriadis
Journal:  J Cent Nerv Syst Dis       Date:  2022-04-01

Review 7.  Outcome measures assisting treatment optimization in multiple sclerosis.

Authors:  Gabriel Pardo; Samantha Coates; Darin T Okuda
Journal:  J Neurol       Date:  2021-08-02       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.